Evidence map›Paper›PMID 28941296›Full record

ArticleSynapse (New York, N.Y.)2018

Ghrelin receptor antagonism of hyperlocomotion in cocaine-sensitized mice requires βarrestin-2.

Krisztian Toth, Lauren M Slosky, Thomas F Pack, Nikhil M Urs, Peter Boone, Lan Mao, Dennis Abraham, Marc G Caron, Lawrence S Barak

Open access · greenAbstract read
In one paragraph

Article in Synapse (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Ghrelin receptor signaling in health and disease: a biased view.Trends in endocrinology and metabolism: TEM · 2023
    Review
  3. Discovery of a functionally selective ghrelin receptor (GHSRProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Krisztian TothDepartment of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710.ORCID 0000-0002-6590-6394
Lauren M SloskyDepartment of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710.
Thomas F PackDepartment of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710.
Nikhil M UrsDepartment of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710.
Peter BooneDepartment of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710.
Lan MaoDepartment of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Dennis AbrahamDepartment of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Marc G CaronDepartment of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710.
Lawrence S BarakDepartment of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710.
Duke University · US

Funding

Akt/GSK-3 Signaling Cascade and the Actions of DopamineR37MH073853 · NIMH · DUKE UNIVERSITY · PI CARON, MARC G. · 2011 to 2020
$6.4M
Science PlanP30DA029925 · NIDA · DUKE UNIVERSITY · PI CARON, MARC G. · 2010 to 2018
$6.2M
Renal Genomics CoreP30DK096493 · NIDDK · DUKE UNIVERSITY · PI COFFMAN, THOMAS M · 2012 to 2016
$5.9M
TREK-1 in fibroblast differentiation and cardiac fibrosis developmentK08HL125905 · NHLBI · DUKE UNIVERSITY · PI ABRAHAM, DENNIS · 2015 to 2019
$746k
Beta-arrestin Regulation of Ghrelin Signaling in Modulating Addictive BehaviorR21DA035421 · NIDA · DUKE UNIVERSITY · PI BARAK, LAWRENCE S. · 2014 to 2015
$429k
Biased Agonism at Neurotensin Receptor 1 for the Treatment of Methamphetamine AddictionF32DA043931 · NIDA · DUKE UNIVERSITY · PI SLOSKY, LAUREN M · 2017 to 2019
$124k
Dissecting the Distinct Arrestin Signaling Capabilities of the Short and Long Dopamine D2 Receptors as a Paradigm for Psychostimulant Addiction TreatmentF31DA041160 · NIDA · DUKE UNIVERSITY · PI PACK, THOMAS FRANKLIN · 2016 to 2017
$67k
NHLBI NIH HHS K08 HL125905NIDA NIH HHS F31 DA041160NIDA NIH HHS F32 DA043931NIDA NIH HHS P30 DA029925NIDA NIH HHS R21 DA035421NIDDK NIH HHS P30 DK096493NIMH NIH HHS R37 MH073853
6 · The paper itself

Abstract

The "brain-gut" peptide ghrelin, which mediates food-seeking behaviors, is recognized as a very strong endogenous modulator of dopamine (DA) signaling. Ghrelin binds the G protein-coupled receptor GHSR1a, and administration of ghrelin increases the rewarding properties of psychostimulants while ghrelin receptor antagonists decrease them. In addition, the GHSR1a signals through βarrestin-2 to regulate actin/stress fiber rearrangement, suggesting βarrestin-2 participation in the regulation of actin-mediated synaptic plasticity for addictive substances like cocaine. The effects of ghrelin receptor ligands on reward strongly suggest that modulation of ghrelin signaling could provide an effective strategy to ameliorate undesirable behaviors arising from addiction. To investigate this possibility, we tested the effects of ghrelin receptor antagonism in a cocaine behavioral sensitization paradigm using DA neuron-specific βarrestin-2 KO mice. Our results show that these mice sensitize to cocaine as well as wild-type littermates. The βarrestin-2 KO mice, however, no longer respond to the locomotor attenuating effects of the GHSR1a antagonist YIL781. The data presented here suggest that the separate stages of addictive behavior differ in their requirements for βarrestin-2 and show that pharmacological inhibition of βarrestin-2 function through GHSR1a antagonism is not equivalent to the loss of βarrestin-2 function achieved by genetic ablation. These data support targeting GHSR1a signaling in addiction therapy but indicate that using signaling biased compounds that modulate βarrestin-2 activity differentially from G protein activity may be required.

Indexed as

Animalsbeta-Arrestin 2Cell Line, TumorCentral Nervous System AgentsCocaineCocaine-Related DisordersDopaminergic NeuronsDopamine Uptake InhibitorsFemaleGhrelinHEK293 CellsHumansMaleMice, Inbred C57BLMice, KnockoutMotor Activitybeta-Arrestin 2Central Nervous System AgentsCocaineDopamine Uptake InhibitorsGhrelinPiperidinesQuinazolinonesReceptors, GhrelinYIL 781addictionarrestincocaineghrelinYIL781

Identifiers

PMID28941296
PMCPMC5705267
OpenAlexW2760672373

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.